No photo of Miles Sparrow

View Scopus Profile

Miles Sparrow

Dr

20062021
If you made any changes in Pure these will be visible here soon.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2006 2021

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active Ulcerative Colitis.

Sparrow, M.

28/08/19 → 31/12/21

Project: Research

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis.

Sparrow, M.

28/08/19 → 31/12/21

Project: Research

A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Naive Subjects with Moderately-to-Severely Active Crohn's Disease.

Sparrow, M.

20/12/18 → 20/01/20

Project: Research

A Phase 2/3, Randomized, Double-blind, Placebo- and Active- controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease (GALAXI).

Sparrow, M. & Hogg, J.

4/10/18 → 30/06/21

Project: Research

Research of inflammatory bowel disease in Australia

Gibson, P. & Sparrow, M.

Ferring Pharmaceuticals Pty Ltd

1/01/06 → 31/12/07

Project: Research

Research Output 2007 2019

Higher Mucosal Healing with Tumor Necrosis Factor Inhibitors in Combination with Thiopurines Compared to Methotrexate in Crohn’s Disease

Vasudevan, A., Raghunath, A., Anthony, S., Scanlon, C., Sparrow, M. P., Gibson, P. R. & van Langenberg, D. R., 15 Jun 2019, In : Digestive Diseases and Sciences. 64, 6, p. 1622-1631 10 p.

Research output: Contribution to journal › Article › Research › peer-review

3 Citations (Scopus)

Anti-TNF re-induction is as effective, simpler, and cheaper compared with dose interval shortening for secondary loss of response in Crohn's disease

Srinivasan, A., Vasudevan, A., McFarlane, A., Sparrow, M. P., Gibson, P. R. & Van Langenberg, D. R., Mar 2018, In : Journal of Crohn's and Colitis. 12, 3, p. 280-288 9 p.

Research output: Contribution to journal › Article › Research › peer-review

Open Access
File
3 Citations (Scopus)

Examining maintenance care following infliximab salvage therapy for acute severe ulcerative colitis

Seah, D., Choy, M. C., Gorelik, A., Connell, W. R., Sparrow, M. P., Van Langenberg, D., Hebbard, G., Moore, G. & De Cruz, P., 1 Jan 2018, In : Journal of Gastroenterology and Hepatology. 33, 1, p. 226-231 6 p.

Research output: Contribution to journal › Article › Research › peer-review

Open Access
File
9 Citations (Scopus)

Exploration of predictive biomarkers of early infliximab response in acute severe colitis: A prospective pilot study

Beswick, L., Rosella, O., Rosella, G., Headon, B., Sparrow, M. P., Gibson, P. R. & van Langenberg, D. R., Mar 2018, In : Journal of Crohn's and Colitis. 12, 3, p. 289-297 9 p.

Research output: Contribution to journal › Article › Research › peer-review

Open Access
File
6 Citations (Scopus)

Low-dose thiopurine with allopurinol co-therapy overcomes thiopurine intolerance and allows thiopurine continuation in inflammatory bowel disease

Vasudevan, A., Beswick, L., Friedman, A. B., Moltzen, A., Haridy, J., Raghunath, A., Sparrow, M. & van Langenberg, D., Jul 2018, In : Digestive and Liver Disease. 50, 7, p. 682-688 7 p.

Research output: Contribution to journal › Article › Research › peer-review